Conduit Non Current Liabilities Total from 2010 to 2024
| CDT Stock | 0.11 0.01 11.00% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 5.9 M | Current Value 5.7 M | Quarterly Volatility 913.4 K |
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Selling General Administrative of 4.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
Conduit |
Latest Conduit Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Conduit Pharmaceuticals over the last few years. It is Conduit Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Conduit Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 4,147,089 | |
| Geometric Mean | 4,068,864 | |
| Coefficient Of Variation | 22.03 | |
| Mean Deviation | 704,142 | |
| Median | 3,707,000 | |
| Standard Deviation | 913,427 | |
| Sample Variance | 834.3B | |
| Range | 2.4M | |
| R-Value | 0.69 | |
| Mean Square Error | 475B | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 140,230 | |
| Total Sum of Squares | 11.7T |
Conduit Non Current Liabilities Total History
About Conduit Pharmaceuticals Financial Statements
Conduit Pharmaceuticals shareholders use historical fundamental indicators, such as Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Conduit Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Conduit Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Conduit Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 5.9 M | 5.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.